Pulmonx Corporation is a commercial-stage medical technology company. The Company provides minimally invasive treatments for chronic obstructive pulmonary disease (COPD). The Companyâs Zephyr Endobronchial Valve, Chartis Pulmonary Assessment System, LungTraX Platform, and StratX Lung Analysis Report are designed to assess and treat patients with severe emphysema/COPD. The LungTraX Platform is a cloud-based quantitative CT (QCT) analysis service that provides physicians with multiple products, LungTraX Connect, to improve workup efficiency, LungTraX Detect, to enable patient identification and an easy-to-read StratX Lung report that it designed for its solution that includes information on emphysema destruction, fissure completeness and lobar volume to help identify target lobes for treatment with Zephyr Valves. The Chartis System is a proprietary balloon catheter and console system with flow and pressure sensors designed to assess the presence of collateral ventilation.
äŒæ¥ã³ãŒãLUNG
äŒç€ŸåPulmonx Corp
äžå Žæ¥Oct 01, 2020
æé«çµå¶è²¬ä»»è
ãCEOãFrench (Glendon E)
åŸæ¥å¡æ°291
蚌åžçš®é¡Ordinary Share
æ±ºç®ææ«Oct 01
æ¬ç€Ÿæåšå°700 Chesapeake Dr
éœåžREDWOOD CITY
蚌åžååŒæNASDAQ OMX - NASDAQ BASIC
åœUnited States of America
éµäŸ¿çªå·94063
é»è©±çªå·16509342600
ãŠã§ããµã€ãhttps://pulmonx.com/
äŒæ¥ã³ãŒãLUNG
äžå Žæ¥Oct 01, 2020
æé«çµå¶è²¬ä»»è
ãCEOãFrench (Glendon E)
éå»5幎éã®é
åœéç·æ¯æé¡ã¯
0.00
ç±³ãã«ã§ããã

ããŒã¿ãªã